Pediatrix Medical Group, Inc.
MD- Exchange
- NYSE
- Industry
- Services-Hospitals
- SEC CIK
- 0000893949
No open-market purchases or sales by Pediatrix Medical Group, Inc. insiders were filed in the last 90 days; 306 institutions reported holding it in 13F filings for Q2 2026, worth $2.12B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Jan 13, 2025 | Feb 20, 2024 | Feb 17, 2023 | Feb 17, 2022 |
| Revenue | $1.91B | $2.01B | $1.99B | $1.97B | $1.91B |
| Operating expenses | $1.71B | $2.08B | $1.99B | $1.80B | $1.71B |
| Selling, general and administrative | $240.8M | $238.4M | $227.5M | $231.4M | $263.4M |
| Operating income | $208.8M | -$68.7M | $7.32M | $172.7M | $202.9M |
| Interest expense | – | – | $42.1M | $39.7M | $68.7M |
| Income tax | $51.0M | -$2.27M | $12.0M | $18.8M | $27.2M |
| Net income | $165.4M | -$99.1M | -$60.4M | $66.3M | $131.0M |
| EPS, basic | $1.97 | $-1.19 | $0.73 | $0.79 | $1.54 |
| EPS, diluted | $1.94 | $-1.19 | $0.73 | $0.79 | $1.53 |
| Weighted shares, basic | 84.1M | 83.3M | 82.2M | 83.5M | 84.8M |
| Weighted shares, diluted | 85.3M | 83.3M | 82.2M | 84.1M | 85.8M |
| Margins and growth | |||||
| Operating margin | 10.9% | -3.4% | 0.4% | 8.8% | 10.6% |
| Net margin | 8.6% | -4.9% | -3.0% | 3.4% | 6.9% |
| Revenue growth, year over year | −4.9% | +0.9% | +1.1% | +3.2% | +10.2% |
| Net income growth, year over year | – | – | −191.1% | −49.3% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Jan 13, 2025 | Feb 20, 2024 | Feb 17, 2023 | Feb 17, 2022 |
| Cash and equivalents | $375.2M | $229.9M | $73.3M | $9.82M | $387.4M |
| Accounts receivable | $229.7M | $260.0M | $272.3M | $296.8M | $301.8M |
| Total current assets | $763.5M | $639.6M | $483.5M | $428.0M | $840.6M |
| Property, plant and equipment | $39.2M | $39.2M | $75.6M | $73.3M | $70.2M |
| Goodwill | $1.26B | $1.24B | $1.38B | $1.53B | $1.51B |
| Intangible assets | $16.9M | $11.6M | $21.2M | $18.5M | $21.6M |
| Total assets | $2.25B | $2.15B | $2.22B | $2.35B | $2.72B |
| Accounts payable | $37.2M | $46.4M | $34.6M | $31.9M | $36.6M |
| Total current liabilities | $458.9M | $434.1M | $388.9M | $427.0M | $427.4M |
| Long-term debt | – | $611.2M | $622.2M | $637.2M | $989.7M |
| Total liabilities | $1.38B | $1.39B | $1.37B | $1.46B | $1.83B |
| Shareholders' equity | $865.9M | $764.9M | $849.1M | $891.6M | $896.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 19, 2026 | Jan 13, 2025 | Feb 20, 2024 | Feb 17, 2023 | Feb 17, 2022 |
| Operating cash flow | $271.1M | $206.6M | $137.3M | $166.9M | $76.7M |
| Depreciation and amortization | $21.8M | $32.2M | $36.2M | $35.6M | $32.1M |
| Stock-based compensation | $18.0M | $11.9M | $12.3M | $16.1M | $19.0M |
| Share buybacks | $86.7M | $1.70M | $919.0K | $88.5M | $4.72M |
| Investing cash flow | -$18.3M | -$35.4M | -$48.2M | -$57.0M | -$53.1M |
| Financing cash flow | -$107.5M | -$14.5M | -$25.7M | -$487.6M | -$760.1M |
| Net change in cash | $145.3M | $156.7M | $63.4M | -$377.6M | -$736.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 0.9% | 0.6% | 0.6% | 0.8% | 1.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 27, 2026 | 78.1M | −9.0% | SEC |
| Jul 31, 2026 | 81.3M | −6.7% | SEC |
| May 1, 2026 | 82.1M | −4.4% | SEC |
| Feb 13, 2026 | 83.0M | −3.3% | SEC |
| Oct 30, 2025 | 85.9M | 0.0% | SEC |
| Aug 1, 2025 | 87.1M | +1.4% | SEC |
| May 2, 2025 | 85.9M | +2.1% | SEC |
| Feb 14, 2025 | 85.8M | +2.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.